SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended	12 Months Ended			1 Months Ended				3 Months Ended	6 Months Ended
	Dec. 31, 2009	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jun. 18, 2013 Protalix Ltd. [Member]	Dec. 31, 2012 Protalix Ltd. [Member]	Dec. 31, 2013 Protalix Bio Therapeutics Inc. [Member]	Dec. 31, 2013 Pfizer Incorporation [Member]	Dec. 31, 2009 Upon Filing of Pediatric Investigation Plan to EMA [Member]	Jun. 30, 2012 Upon FDAApproval [Member]
Significant Accounting Policies [Line Items]
Number of Subsidiaries		2
Pfizer Agreement, upfront payment received	$ 60,000								$ 5,000
Milestone payment triggered										25,000
Pfizer Agreement, future revenues and expense sharing percentage							40.00%	60.00%
Common stock, par value per share		$ 0.001	$ 0.001
Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive		10,675,304	7,280,469	7,469,088
Supply commitment for entitled rights to be received					280,000
License and supply agreement potential future payment					12,500
Supply commitment per year					40,000
Eligable payment receivable upon achievement						$ 8,300